ResearcherShanghai University of Traditional Chinese MedicineActive in the last 2 years

Kui Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1165-8505; OpenAlex author ID A5103099433. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

CUL2 confers ferroptosis resistance in pancreatic cancer by disrupting KEAP1-mediated NRF2 degradation. Co-author DOI 10.1186/s12935-025-04005-4 ↗
Solasonine Inhibits Pancreatic Cancer Progression With Involvement of Ferroptosis Induction. Co-author DOI 10.3389/fonc.2022.834729 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Dachuan Qi · 1 shared paper, 2025 · strength 0.25
- Paper CUL2 confers ferroptosis resistance in pancreatic cancer by disrupting KEAP1-mediated NRF2 degradation. DOI 10.1186/s12935-025-04005-4 ↗
Lijuan Yang · 1 shared paper, 2025 · strength 0.25
- Paper CUL2 confers ferroptosis resistance in pancreatic cancer by disrupting KEAP1-mediated NRF2 degradation. DOI 10.1186/s12935-025-04005-4 ↗
Xiaoqiang Liang · 1 shared paper, 2022 · strength 0.16
- Paper Solasonine Inhibits Pancreatic Cancer Progression With Involvement of Ferroptosis Induction. DOI 10.3389/fonc.2022.834729 ↗
Jingzhe Zhang · 1 shared paper, 2022 · strength 0.16
- Paper Solasonine Inhibits Pancreatic Cancer Progression With Involvement of Ferroptosis Induction. DOI 10.3389/fonc.2022.834729 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.